New hope for rare disease wounds: drug access expanded
NCT ID NCT04914247
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This program provides selexipag (Uptravi) to patients with Buerger's disease who have a non-healing wound. The goal is to help heal the wound and control the disease. Only a single patient is enrolled in this expanded access program.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HEALING WOUND are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.